What’s Next? Five Things To Look Out For In February

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

What's Next Image
Source: Norstella

The floodgates are due to open for US biosimilar competition to Stelara (ustekinumab) in February, with a multitude of ustekinumab biosimilars that have received US Food and Drug Administration approval set to launch under the terms of patent-litigation settlement agreements.

Partners Alvotech and Teva – which gained approval for their Selarsdi (ustekinumab-aekn) version in April –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Sandoz Leads Charge With First US Denosumab Launch

 
• By 

Competition to Amgen’s Prolia and Xgeva denosumab brands has hit the US market, with Sandoz taking the lead by launching its interchangeable Jubbonti and Wyost biosimilars.

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By 

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By 

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.